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 NAFLD     -      Non Alcoholic Fatty Liver Disease 
 PBC          -      Primary Biliary Cirrhosis 
 PSC          -       Primary Sclerosing Cholangitis 
 MPGN      -       Membrano Proliferative Glomerulo Nephritis 
 HHT         -       Hereditary Hemorrhagic Telangiectasia 
 PDGF       -       Platelet Derived Growth Factor 
 MAP         -      Mean Arterial Pressure 
 INR          -       International Normalized Ratio 
 AST          -      Aspartate Amino Transferase 
 ALT          -      Alanine Amino Transferase 
 ALP          -      Alkaline phosphatase 
 GGT         -       Gamma Glutamyl Transferase 
 NT            -      Nucleotidase 
 HCC         -       HepatoCellular Carcinoma 
 TIPS         -       Transjugular Intrahepatic PortoSystemic Shunt 
 RAAS       -       Renin Angiotensin Aldosterone System 
 ADH         -      Anti Diuretic Hormone 
 BRTO       -       Balloon Occluded Retrograde Transvenous Obliteration 
 HPS          -      HepatoPulmonary Syndrome 
 POPH       -       Porto Pulmonary Hypertension 
 HRS          -      Hepato Renal Syndrome 
 MELD       -      Model For End Stage Liver Disease 
 BMI          -      Body Mass Index 
 T3             -      Tri Iodo thyronine 
 T4             -      Thyroxine 
 TSH          -      Thyroid Stimulating Hormone 
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INTRODUCTION 
Chronic liver disease refers to a disease of the liver characterized by 
progressive destruction associated with regeneration of the liver parenchyma 
ultimately resulting in fibrosis and cirrhosis. Chronic refers to disease process 
which lasts for over six months.18 
Cirrhosis of liver is a histopathological diagnosis. It results in numerous 
complications such as  
1. Ascites 
2. Spontaneous bacterial peritonitis 
3. Portal hypertension  with variceal bleeding 
4. Hepatic encephalopathy 
5. Hepatorenal syndrome 
6. Hepatopulmonary syndrome 
7. Hepatocellular carcinoma 
8. Coagulation disorder 
9. Endocrine dysfunction 
Endocrine dysfunction includes derangements in the functions of 
adrenal gland, disturbances in the gonadal axis, bone diseases and thyroid 
dysfunction3.  
Liver plays a pivotal role in thyroid hormone metabolism. It also 
produces thyroid hormone binding globulin, albumin that are essential for 
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binding thyroid hormones in circulation and delivering them to various body 
tissues. Chronic liver disease is associated with a low T3 syndrome. 
Low T3 syndrome is characterized by low levels of T3, increased rT3 
and decreased T3:T4 ratio. The reduced levels of T3 serves as an adaptive 
response to reduce the basal metabolic rate of hepatocytes and preserve liver 
function. T4 levels tend to be in the lower limits of normal range whereas TSH 
tends to remain in the normal range. 
There appears to be an inverse correlation between the levels of T3 and 
the Child Pugh score and class. The levels of T3 are found to be significantly 
lower as the level of decompensation  worsens. Thus serum free T3 levels can 
be used as a reliable prognostic marker in patients with cirrhosis. The levels of 
T3 tends to improve as the patient’s liver function improves. 
CHILD-TURCOTTE-PUGH CRITERIA 
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AIMS AND OBJECTIVES 
 
To study the thyroid function tests in decompensated chronic liver 
disease and to determine the importance of Free T3 levels as a prognostic 
indicator in patients with decompensated chronic liver disease. 
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REVIEW OF LITERATURE 
DEFINITION 
The term chronic liver disease in clinical context refers to the disease 
process of the liver that causes progressive destruction and regeneration of liver 
parenchyma that leads to cirrhosis and fibrosis. Chronicity denotes disease 
process which lasts over six months. It encompasses a wide spectrum of 
disease process which includes inflammation (chronic hepatitis), liver cirrhosis 
and hepatocellular carcinoma.40 
Common causes of cirrhosis include: 
1. Chronic viral hepatitis (hepatitis B and hepatitis c) 
2. Alcoholic liver disease 
3. Nonalcoholic fatty liver disease 
The word cirrhosis is derived from the greek word ‘kirrhos” meaning 
“yellow/tawny” and the suffix “osis” meaning “condition”. The term was 
coined by Rene Laennec. The term cirrhosis refers to the final common 
pathway for the wide array of chronic liver diseases which results in 
replacement of the normal liver architecture by nodules. The rate of 
progression of chronic liver disease to cirrhosis varies from patient to patient. 
It is irreversible in advanced stages where liver transplantation remains 
the only viable treatment option. Rarely, in early stages with treatment cirrhosis 
has been shown to be reversible. Cirrhosis makes the patients vulnerable to a 
 variety of complications and this is resu
expectancy with a 10 year mortality of 34 to 66%, depending on the cause of 
cirrhosis. 
ETIOLOGIES OF CIRRHOSIS
5 
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 COMPLICATIONS OF CIRRHOSIS
PATHOGENESIS OF CIRRHOSIS
It is the final common result of various chronic liver diseases. Fibrosis is 
the precursor of cirrhosis. Various types of cells, cytokines and miRNA are 
involved in the initiation and progression of liver fibrosis and cirrhosis. Hepatic 
stellate cell activation is the main event in fibrosis. There is defenestration and 
capillarization of liver sinusoidal endothelial cells. The kupffer cells cause 
destruction of hepatocytes and activates 
of apoptosis and regeneration o
In recent decades NAFLD is emerging as a leading cause of chronic liver 
disease with prevalence as high as 30% in general population.
hepatic stellate cells resemble pericytes that lies in the 
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7 
 
sinusoidal endothelial cell in the space of Disse. Stimulus for activation of 
hepatic stellate cells leads to transformation into a myofibroblast. This 
transformation is characterized by increased expression of smooth muscle 
actin, motility and contractility. The activated stellate cells lay down various 
forms of matrix proteins such as fibronectin, collagen 1. This matrix generation 
leads to further activation of HSCs and alteration in hepatic angioarchitecture. 
These pathways are mediated by kinase activation pathways that are mediated 
by PDGF, TGF-B and integrin.18,40 
Other cell type implicated in cirrhosis include portal fibroblast. It resides 
closer to portal tract and is considered to be responsible for liver fibrosis that 
develops in portal based pathologies such as PBC and PSC. Epithelial injury in 
periportal region leads to transformation of portal fibroblasts to myofibroblasts. 
Cells other than myofibroblasts also play a pivotal role in pathogenesis of 
cirrhosis.Macrophages are also implicated in development of cirrhosis. They 
release inflammatory cytokines which cause HSC activation.  
There are studies showing role of sinusoidal endothelial cells in fibrosis. 
They act through autocrine and paracrine signaling pathways that participate in 
angiogenesis. Angiogenesis in turn leads to fibrosis via paracrine release of 
HSC activating molecules. Inspite of involvement of multiple cell types in 
development of fibrosis, the hepatic stellate cells are most directly responsible 
for cirrhosis owing to its abundant capacity to produce matrix. 
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CLINICAL AND PATHOLOGICAL ASSOCIATIONS 
1: Gastrointestinal 
The presence of splenomegaly and venous collaterals signifies portal 
hypertension. About 11% of patients with cirrhosis tend to have peptic 
ulceration. Duodenal ulcers are more frequent than gastric ulcers. Patients with 
cirrhosis tend to have greater prevalence of helicobacter pylori on serology. 
Bacterial overgrowth occurs in about 30% of patients with cirrhosis and 
concomitant ascites. There is a positive correlation between administration of 
H2 blockers/PPIs and prevalence of bacterial overgrowth. The prevalence 
increases with age of the patient. 
In patients with ascites there is an increased incidence of abdominal 
hernia. Surgical correction of hernia is usually deferred unless there is danger 
to life or in the presence of well compensated cirrhosis. 
Pigment type gall stones are common in cirrhotics. Patients are poor 
candidates for surgical management of gall stones. Pancreatic calcifications and 
relapsing pancreatitis are usually associated with chronic liver disease. Parotid 
enlargement is usually noticed. 
2: Renal 
Hemodynamic alterations in cirrhosis predisposes the patient to Hepato 
Renal Syndrome. There is thickening of mesangial stalk along with capillary 
walls. Hepatitis C infection is associated with cryoglobulinemia and MPGN. 
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3:Foetor Hepaticus 
The presence of dimethyl sulphide and ketones in alveolar air gives rise 
to a slightly fecal smell of breath which complicates severe hepatocellular 
disease and signifies existence of extensive collateral circulation. It can serve 
as a useful diagnostic sign in patients presenting with coma. 
4:Vascular Spiders 
They are found in the vascular territory of superior vena cava in the 
necklace area, face, forearms and dorsum of hand. It consists of a central 
arteriole with numerous small vessels radiating from it resembling the legs of a 
spider. It blanches on applying pressure. They can be of prognostic value since 
they disappear as the hepatic function improves and tend to reappear as it 
worsens. The presence of multiple spider naevi along with clubbing of nails 
should invoke a suspicion of hepatopulmonary syndrome. The skin of 
cirrhotics resembles the silk threads in American dollar bills and hence the 
name paper money skin. There is appearance of white spots that develops in the 
arms and buttocks on cooling the skin. They represent the beginning of a spider 
naevi. Spider naevi can be present in other conditions like pregnancy, in young 
children. Other differentials include HHT, CREST syndrome, Campbell de 
Morgan’s spots, Venous star.  
 5: Palmar Erythema
A blanching erythematous rash can be observed in the thenar and 
hypothenar eminences with sparing of the centre of the palm. They are also 
appreciated in the soles. There can be associated throbbing pain and tingling of 
the hands. It is not a very common manifestation in cirrhotics
The vascular spiders and palmar erythema occur 
estrogen in circulation that results in vasodilatation.
6:Leuconychia 
The presence of white finger nails are related to hypoalbuminemia
12 
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 7:Clubbing 
Clubbing though uncommon in cirrhosis, can be seen in cases of cystic 
fibrosis or hepato pulmonary syndrome. They are primarily due to platelet 
aggregation that passes peripherally through pulmonary AV shunts and causing 
release of PDGF. 
8:Dupuytren’s Contracture
It is seen in alcoholic cirrhosis as a result of thickening of the palmar 
fascia in the hand. 
9:Malnutrition 
Reduced intake of food with increased energy expenditure results in 
protein-calorie malnutrition and predicts shortened survival in cirrhotics. 
Patient experience reduced muscle mass and depleted fat stores with resultant 
muscle weakness and muscle wasting. Reduced hepatic bile salt production can 
give rise to steatorrhoea. Triceps skin fold thickness, BMI, mid arm muscle 
circumference can be used for bedside assessment of nutritional status
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 10:Hyperglycemia 
Upto 80% of c
10 – 20% developing diabetes. 
11:Hypogonadism 
Males tend to experience reduced libido and impotence with loss of 
secondary sexual characters and testicular atrophy. Females have ovulation 
failure, can develop infertility, irregular menstrual cycles. Tender 
gynaecomastia can develop in men as a result of drugs or alcohol induced 
enlargement of glandular elements of breast or in chronic autoimmune 
hepatitis. End organ sensitivities to sex hormones is 
Feminization can also signal primary liver cancer occasionally.
pituitary dysfunction is also present.
MECHANISM OF HYPOGONADISM IN CIRRHOSIS
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altered in cirrhotics. 
3,5,15,18
 
 
 
 Hypothalamic-
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12:Eye signs 
The incidence of lid retraction and lid lag is significantly increased in 
cirrhotics compared to control population. 
13:Muscle cramps 
They correlate with presence of ascites, low MAP and plasma renin 
activity. They can be managed with oral quinine sulphate 
14:Drug metabolism 
There is reduced hepatic elimination of drugs with resultant increase in 
drug levels. This can be explained by reduced functional hepatic mass and 
shunting of blood past the liver. The dosage of drugs should be adjusted 
according to severity of the disease. There is also altered drug absorption, drug 
distribution, reduced protein binding, altered biliary secretion, enterohepatic 
circulation and unresponsiveness of target organs. 
DIAGNOSIS OF CIRRHOSIS 
Cirrhosis is a histological diagnosis. Constellation of clinical, 
biochemical and radiological features can give clues to a diagnosis of cirrhosis. 
Liver biopsy is not always needed to establish a diagnosis of cirrhosis. Markers 
of hepatic fibrosis from hematologic parameters, biochemical tests and 
serology are available to determine the extent of liver fibrosis. 
 
16 
 
LIVER FUNCTION TESTS 
The battery of investigations that are useful in evaluating the functions 
of the liver include  
1. Total bilirubin and direct bilirubin 
2. Albumin 
3. Prothrombin time/ INR 
4. AST/ALT 
5. ALP 
6. GGTP/5’NT 
The liver function tests can give an insight in establishing the etiology of 
the disease, differentiating the type of liver disorder, in assessing the severity of 
the disease as well as monitoring the disease progression and response to 
therapy. 
I - TESTS BASED ON EXCRETORY FUNCTION 
1. Serum bilirubin 
2. Urine bilirubin 
3. Urine and fecal urobilinogen 
4. Urine bile salts 
5. Dye excretion tests 
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II - TESTS BASED ON DETOXIFICATION FUNCTION 
1. Determination of blood ammonia 
2. Hippuric acid test 
III - TESTS BASED ON SYNTHETIC FUNCTION 
1. Plasma proteins 
2. Prothrombin time 
IV - TESTS BASED ON METABOLIC FUNCTION 
1. Galactose tolerance test (carbohydrate metabolism) 
2. Serum cholesterol (lipid metabolism) 
3. Serum proteins and aminoaciduria (protein metabolism) 
V - ENZYMES IN DIAGNOSIS OF LIVER DISEASE 
1. Serum transaminases 
2. Serum alkaline phosphatase 
VI – TESTS TO DETECT HEPATIC FIBROSIS 
1. Liver biopsy 
2. Hyaluronan measurement 
3. Fibrotest 
4. Transient elastography and Magnetic resonance elastography 
 
 
 VII – QUANTITATIVE LIVER FUNCTION TESTS
1. Indocyanin green clearance and 
2. Galactose elimination capacity and Lidocaine metabolite formation
3. Aminopyrine breath test
FUNCTIONS OF LIVER
Liver participates in storage, degradation of hormones, metabolism, 
synthesis. Derangement of liver function can manifest with
abnormalities in anyone of these aspects. Laboratory investigations focused at 
these functions can throw light on the extent of liver damage, the probable 
etiology and the prognosis. Serial evaluation  the liver function tests can help 
predict response to treatment and recovery from illness.
 
 
18 
 
caffeine clearance 
 
 
 
 
 
 functional 
 APPROACH TO A PATIENT WITH ELEV
 
19 
ATED BILIRUBIN
 
 
 
 CAUSES OF HYPERBILIRUBINEMIA
CAUSES OF ELEVATED TRANSAMINASES
 
 
20 
 
 
 
 
 INTERPRETATION OF ABNORMAL LFT
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 LFT PATTERNS IN HEPATOBILIARY DISORDERS
Establishing a pattern of liver disease at the end of liver function testing 
can help the clinician in further evaluation of the disease process. These tests 
need to be repeated on several instances over days to week to embark upon a 
diagnostic pattern. Th
from region to region. Infectious diseases tend to cause more cases of chronic 
liver disease in developing nations when compared with developed nations. 
The most effective way to increase the specifi
function testing is to combine a battery of investigations namely bilirubin, 
aminotransferases, prothrombin time, albumin, alkaline phosphatase along with 
judicious use of other investigations to establish the etiology.
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city and sensitivity of the liver 
 
 
 
 NATURAL HISTORY OF THE DISEASE
Cirrhosis can be classified as either compensated or decompensated 
depending upon the development of complications.
Decompensation refers to the development of complications in the form 
of variceal hemorrhage, ascites, hepatic 
hepatocellular carcinoma. These complications are not present in compensated 
cirrhosis. 4 clinical stages of cirrhosis has been defined
Stage 1 – absence of both ascites and varices
Stage 2 – presence of varices without bleeding
Stage 3 – ascites with or without esophageal varices
Stage 4 – variceal bleeding with or without ascites
The most common cause of death in cirrhosis is due to development of  
hepatic decompensation namely portal hypertension, HCC an
of compensated cirrhosis death occurs due to cardiovascular cause or stroke or 
malignancy or renal disease.
23 
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I – ASCITES 
 The term ascites refers to the presence of free fluid within the peritoneal 
cavity. It can be caused due to cirrhotic or non cirrhotic causes. Cirrhosis 
remains the commonest cause of ascites. Non cirrhotic causes of ascites include 
peritoneal malignancy, cardiac failure and peritoneal tuberculosis.  
Though there are different mechanisms of ascites formation presence of 
portal hypertension and renal sodium retention remains universal. It progresses 
through stages of diuretic responsiveness to dilutional hyponatremia, refractory 
ascites and can terminate in Hepato renal syndrome.  
The transition from simple ascites to the stage of diuretic resistant 
ascites leads to decline in 1 year survival rate from 85% to 25%. The treatment 
of ascites is important in improving the quality of life, to avoid development of 
spontaneous bacterial peritonitis (SBP). Though newer treatments such as TIPS 
are being evaluated for treatment of refractory ascites Liver transplantation 
remains the ultimate therapy for ascites and should also always be considered 
when the patient presents for the first time with ascites.  
Theories Of ascites formation: 
The factor which initiates leakage of ascites into the peritoneal space is 
the sinusoidal hypertension. The regenerative nodules and fibrosis leads to 
hepatic venous outflow block and sinusoidal hypertension. The central event in 
the development of ascites is sodium and water retention which replenishes the 
intravascular volume and maintains the ascites formation. 
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The development of ascites requires a minimal portal pressure gradient 
of 12mm Hg. Clinically significant portal hypertension refers to portal pressure 
gradient of 10mm Hg. Urinary sodium excretion is usually less than 
5mmol/day. There is avid sodium retention even in the absence of ascites. 
 
 
“Vasodilatation theory” is based upon the fact that altered 
hemodynamics in cirrhosis with arterial vasodilatation is the most likely cause 
of sodium retention. The vasodilatation is the result of excess production of 
nitric oxide (NO). other agents implicated in the peripheral vasodilatation 
includes carbon monoxide, adrenomedullin, endocannabinoids, prostacyclin, 
tumor necrosis factor alpha and urotensin. The arterial vasodilatation results in  
26 
 
reduced effective arterial blood volume and fall in systemic pressure which 
results in the activation of RAAS and sympathetic system. There is 
downstream release of aldosterone from adrenal gland. The aldosterone acts 
upon the renal tubules and results in reabsorption of sodium.  
Angiotensin 2 also leads to release of ADH and activation of adrenergic 
system. 
 
 “Overfill theory” is based upon the presence of renal sodium handling 
abnormalities in the absence of systemic vasodilatation or under filling. There 
is excess reabsorption of sodium and water which leads to expansion of plasma 
volume and increases cardiac output with a fall in systemic vascular resistance. 
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Ascites due to cirrhosis and elevated portal pressure gradient gives rise 
to a high SAAG (serum ascites albumin gradient) more than or equal to 1.1g/dl. 
The first line of management of ascites is salt restricted diet upto 2g/day. If this 
is ineffective then patient is started on oral diuretics. Frusemide and 
spironolactone are usually used. They can be titrated to achieve a maximum 
dose of 160mg for frusemide and 400mg for spironolactone. The term 
refractory ascites is given to free fluid in the abdomen despite optimal salt 
restriction and maximal dose of diuretics. 
Refractory ascites can be managed with pharmacological agents such as 
midodrine or clonidine which acts by counteracting splanchnic vasodilatation. 
Beta blockers tend to reduce survival rates in patients with refractory ascites. It 
can also be managed with large volume paracentesis or TIPS. Large volume 
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paracentesis should be accompanied by albumin infusions to prevent 
circulatory dysfunction. 
Complications of ascites include spontaneous bacterial peritonitis, 
hepatic hydrothorax and hepatorenal syndrome. 
II – PORTAL HYPERTENSION 
Capillary blood from the esophagus, stomach, small and large intestine, 
pancreas, gall bladder and spleen are carried via the portal venous system to the 
liver. It a high compliance and low pressure system. There is dual blood supply 
to the liver from mesenteric venous circulation (75%) and the remainder from 
hepatic artery. Liver consists of an inherent auto regulatory mechanism which 
helps in maintaining the total hepatic blood flow at a constant rate. 
Portal hypertension arises as a result of change in portal resistance and 
change in portal blood flow. These changes can arise as a result of mechanical 
and vascular factors. Fibrosis and regenerative nodules constitute the 
mechanical factors. There are numerous mediators that result in intrahepatic 
vasoconstriction with splanchnic and  peripheral vasodilatation. 
Elevated portal pressure leads to development of porto-systemic 
collaterals. The flow pattern in collaterals is reversed and blood flows away 
from the liver towards the systemic circulation. The sites of collaterals include 
distal esophagus, proximal stomach, umbilicus, retroperitoneum, rectum. 
 
      There are four zones of venous drainage in the distal esophagus that is 
important to the understanding of the development of esophageal varices. This 
includes 
1. The gastric zone 
2. The palisade zone 
29 
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– do not communicate with periesophageal veins
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3. The perforating zone – connects esophageal submucosal veins and 
periesophageal veins 
4. The truncal zone – longitudinal veins in lamina propria.  
    The palisade zone is most prone for bleeding since there is no perforating 
veins connecting the submucosal veins with periesophageal veins.40 
     Patients with intrahepatic cause of portal hypertension most commonly 
present with esophageal/gastric varices in continuity with esophageal varices. 
This requires a portal pressure gradient of 10mm Hg to develop. Increase in 
this gradient to 12mm Hg is required for the varices to bleed. Hepatic vein 
pressure gradient(HVPG) is an indirect method of measuring portal pressure. It 
is the difference between wedged hepatic venous pressure(WHVP) and free 
hepatic vein pressure(FHVP). It measures the gradient between portal vein and 
the intra abdominal inferior vena cava. 3 measurements are done in order to 
ensure reproducibility. Its uses include 
1. Monitoring of portal pressure in patient taking drugs to prevent variceal 
bleeding 
2. For prognostification 
3. In clinical trials to asses drug efficacy 
4. Risk of hepatic resection in patient with cirrhosis 
5. To identify the cause of portal hypertension. 
      Other less common methods of
system includes splenic pulp pressure, portal vein pressure,endoscopic variceal 
pressure.  
CLASSIFICATION OF PORTAL HYPERTENSION
31 
 assessing the pressure in the portal 
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     Approximately one third of cirrhotics have varices and 5 to 15% of 
cirrhotics per year develop varices. One third of patients with varix develop 
bleeding. Portal hypertension is ameliorated by reducing the  blood flow  or 
decreasing intrahepatic resistance.  
          Pharmacologic agents act either by decreasing the splanchnic blood flow 
or by decreasing the intrahepatic vascular resistance.  
1. Vasopressin analogs can be used for acute reduction of splanchnic blood 
flow. There can be systemic adverse effects resulting in 
vasoconstriction, negative inotropic/chronotropic effects on the 
myocardium. There is a possibility of  increased afterload which can 
precipitate an episode of myocardial infarction. It can induce diuresis by 
acting on the kidney and can result in hyponatremia. Terlipressin can be 
used in combination with nitrates to reduce the systemic adverse effects. 
2. Somatostatin and its analogs can cause reduction in portal blood 
pressure and reduce the collateral blood flow by inhibiting the release of 
glucagon.  It can also bring about a decrease in portal pressure by 
reducing the splanchnic blood flow. 
3. Beta blockers especially non selective beta blockers such as propranolol 
or nadolol are used. They cause decreased cardiac output, inhibits the 
mesenteric vasodilatation which brings about a decrease in portal blood 
flow.  Measurement of HVPG can be done to asses the efficacy of beta 
blockers. Clinically a fall in heart rate can be used as a guide to titration 
of beta blockers. Beta blockers are detrimental in late stages of liver 
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disease and also in cases of refractory ascites it tends to increase the 
mortality. 
4. Combined alpha and beta blockade. Carvedilol has non selective beta 
blockade along with a weak alpha receptor blocker activity. Carvedilol 
can cause hypotension and renal sodium retention. It has added 
antioxidant and anti proliferative properties. It reduces the incidence of 
rebleeding with significantly better adverse drug reaction profile. 
Increase in doses are heralded by the development of hypotension. 
5. Nitrates result in venodilataion and brings down the portal pressure by 
reducing the portal venous blood flow. It is usually used in combination 
with a beta blocker to prevent episodes of rebleeding. 
6. Other agents used are prazosin, losartan, simvastatin, ET blockers and 
NO donors. 
7. Other treatment modalities include sclerotherapy, variceal ligation, 
detachable snares, balloon tamponade, stents, TIPS, BRTO. 
8. Surgical treatment modalities can be either non shunt procedures  
(esophageal transection, devascularization)or portosystemic shunt 
procedures (selective shunts, partially selective shunts, portocaval 
shunts, mesenterico-left portal venous bypass). 
 III – HEPATIC ENCEPHALOPATHY
It is a state of  reversible neuropsychiatric symptoms that primarily 
results from accumulation of waste products especially ammonia by the liver. It 
has important implications on the patient survival. There can be either mild 
neurocognitive disturbance or frank coma. It is usually precipitated by an 
inciting event and elimin
for removal of excess ammonia is the mainstay treatment. Liver 
can also reverse HE. 
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ation of the inciting event along with pharmacotherapy 
 
 
transplantation 
 PATHOPHYS
There are 3 major categories of HE
1. Type A – associated 
2. Type B – associated with portosystemic shunts without liver disease
3. Type C – associated with chronic liver disease
     Type C is the most common and can be further divided based on west 
haven criteria. Treatment of hepatic encephalopathy includes the use of non 
absorbable disaccharides (lactulose or lactitol). 
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IOLOGY OF HEPATIC ENCEPHALOPATHY
 
with acute liver failure 
 
 
 
 
 
 
 GRADING OF HEPATIC ENCEPHALOPATHY
Oral antibiotics are als
intestinal bacterial flora and lowering of stool pH to promote excretion of 
ammonia. Rifaximin 550mg BD is widely used. Other agents include use of 
neomycin, metronidazole, vancomycin.
Sodium benzoate, sodium ph
enhance the excretion of ammonia in the urine. Zinc can also help in 
improvement of hepatic encephalopathy. MARS (molecular adsorbent 
recirculating system), albumin dialysis can also be tried. The role of LOLA has 
also been validated in many clinical trials and can alleviate the degree of 
hepatic encephalopathy.
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o used to treat HE. The aim is to modify the 
 
enylbutyrate and sodium phenylacetate can 
 
 
 
 IV – HEPATOPULMONARY SYNDROME AND PORTOPULMONARY 
HYPERTENSION 
Hepatopulmonary syndrome results from alterations in the pulmonary 
microvasculature that lea
vasoconstriction and remodeling in resistance vessels. They indicate increased 
mortality rates in affected patients. HPS is associated with increased levels of 
NO in the pulmonary circulation that results in v
in the pulmonary microvasculature. POPH histologically resembles other forms 
of pulmonary arterial hypertension. It is more common in women. The classic 
manifestations of HPS includes platypnea and orthodeoxia. Presence of 
clubbing and arterial hypoxemia in the absence of other cardiopulmonary 
disease should lead to a suspicion of HPS in patients with cirrhosis. The 
symptoms worsen over time. There is marked hypoxemia during sleep. IV 
contrast echocardiography can be used to d
shunting of blood. 
37 
ds to impaired gas exchange. POPH results from 
asodilatation and angiogenesis 
etect presence of intrapulmonary 
 
 
      POPH is characterized by exertional dyspnea. Physical examination can 
reveal signs suggesting pulmonary arterial hypertension. Presence of peripheral 
edema out of proportion to ascites should lead
superadded right ventricular dysfunction resulting from POPH. Initial 
echocardiographic evaluation suggesting right ventricular dysfunction should 
be subjected to pulmonary artery catheterization.
     HPS reversed in u
the treatment of choice. Liver transplantation i
of POPH because of the presence of right ventricular dysfunction. Pre 
treatment with medications to lower pulmonary vasc
transplantation in such patients. Diuretics are used in POPH to reduce preload. 
Prostacyclin analogs, ET antagonist, PDE 5 inhibitors can be tried.
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 to suspicion of the presence of a 
 
pto 80% of patients with liver transplantation and is 
s contraindicated in the presence 
ular resistance can permit 
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V – HEPATORENAL SYNDROME 
Hepatorenal syndrome is linked to the cascade of altered hemodynamics 
that is present in patients with cirrhosis of liver. There is intense renal 
vasoconstriction which leads on to development of renal failure with 
anatomically normal kidneys. It is essential to recognize and treat hepatorenal 
syndrome as it is linked to reduced survival in patients with established liver 
disease. 
          The 3 events which has been postulated in the initiation and progression 
of hepatorenal syndrome are 
1. Splanchnic and systemic arterial vasodilatation 
2. Renal vasoconstriction 
3. Cardiac dysfunction 
 
 
 
 
 
 
 
(continued) 
 PATHOPHYSIOLOGY OF HRS
The diagnosos of hepatorenal syndrome requires exclusion of other 
causes of renal dysfunction. The patients are asymptomatic from renal failure. 
The raising BUN can precipitate encephalop
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athy. 
 
 DIAGNOSTIC CRITERIA FOR HRS
There are two types of HRS
Type 1: 
 Usually triggered by an inciting event
 SBP is the most common inciting event
 Rapidly progressive renal dysfunction
 Serum creatinine levels are usually above 2.5mg/dl
Type 2: 
 Slower compared to type 1 HRS
 Usually observed in patients with severe diuretic resistant ascites 
 Serum creatinine levels are usually less than 2.5mg/dl
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 CRITERIA FOR DIAGNOSIS OF KIDNEY DYSFUNCTION IN 
PATIENTS WITH CIRRHOSIS
Management of HRS includes
 Correction of intravascular volume depletion
 Treating underlying infections
 Avoidance of nephrotoxic drugs
 Therapeutic options include medical therapy, TIPS and liver 
transplantation
 The therapies aim at reversing the systemic and splanchnic 
vasodilatation with
circulating volume with use of colloid followed by definitive 
treatment –
42 
 
 
 
 
 
 
 vasoconstrictors and increasing the effective 
 liver transplantation 
 
  Extracorporeal albumin dialysis with MARS, use of dopamine and 
use of non selective endothelin receptor antagonis
demonstrated benefits on a large scale
MANAGEMENT OF HRS
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t have not 
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VI - COAGULATION DISORDERS 
          Loss of functional hepatocytes results in deficiency of procoagulant 
factors that are dependent on vitamin K (2,7,9,10), factor 5 and factor 11. There 
is a prolonged prothrombin time with increased risk of bleeding. This can be 
managed by transfusion of fresh frozen plasma, vitamin K and factor VIIa. INR 
is used in prediction of survival in cirrhotics by used of MELD scoring and also 
in prioritizing patients with liver disease for transplantation. 
           Presence of thrombocytopenia can indicate portal hyptertension leading 
on to hypersplenism. The platelet counts can also be decreased as a result of 
reduced thrombopoietin synthesis and bone marrow toxicity. There is also 
impaired platelet thrombin generation and as result there is impaired clot 
formation. However there is no direct increase in the risk of bleeding and hence 
routine transfusion of platelets are not indicated. 
Cirrhosis leads on to dysfibrinogenimia that manifests either as hyper or 
hypofibrinolysis. There is also impaired production of endogenous 
anticoagulant proteins resulting in a state of hypercoagulability and risk of 
thrombosis. However there are no definite guidelines regarding the role of 
anticoagulation in preventing portal vein thrombosis in case of chronic liver 
disease.  
Thromboelastography can asses components of  clot formation, clot 
strength and stability. They can be used as a predictive tool in determining the 
risk of rebleeding from esophageal varices. Studies show that despite multiple 
coagulation abnormalities they tend to maintain a balanced homeostatic milieu. 
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VII – ENDOCRINE DYSFUNCTION 
Cirrhosis is associated with numerous endocrine abnormalities such as5  
1. Adrenal insufficiency 
2. Gonadal dysfunction 
3. Bone disease 
4. Thyroid dysfunction 
1. Adrenal insufficiency 
Both compensated and decompensated liver disease is associated with a 
state of relative adrenal insufficiency. This results in greater hemodynamic 
instability with increased mortality. The proposed mechanisms of adrenal 
insufficiency in liver disease are as follows 
- Inadequate hepatic cholesterol production resulting in insufficient 
release of adrenal cortisols during periods of stress. 
- Adrenal insufficiency due to increased levels of endotoxins and 
circulating cytokines. 
There is no sufficient data regarding the benefit of glucocorticoid 
supplementation in patients with liver disease. 
2. Gonadal dysfunction 
     Cirrhotics tend to experience both central and peripheral hypogonadism. 
There is increase in  levels of sex hormone binding globulin (SHBG) which 
binds testosterone and 17B – estradiol with relatively lower affinity for 
estrogens. There is relative increase in the levels of SHBG with reduced 
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synthesis of dehydroepiandrosterone sulfate which is the cause of the 
feminization syndrome seen in male patients with cirrhosis.5,16,19  
     Alcohol has direct effects on the leydig cells and also on the 
hypothalamo – pituitary – gonadal axis. This leads to a decrease in the serum 
levels of luteinizing hormone and reduced responsiveness to gonadotropin 
releasing hormone.  
          Spironolactone which is used in treatment of ascites in cirrhotics 
displaces androgen from its receptor and binding protein and also causes 
increased levels of estradiol with increased clearance of testosterone from the 
circulation thus leading to the development of painful gynecomastia. The role 
of testosterone supplementation in cirrhotics is not validated.37 
3. Bone disease 
There is increased risk of osteoporosis among the cirrhotics with the risk 
factor being presence of cholestasis, a maternal history of hip fracture, alcohol 
consumption, progression of liver disease, low BMI, glucocorticoid use for 
more than 3 months and age. Bone mineral density scan can be used as a 
screening tool to detect osteoporosis in cirrhotics especially in patients with 
primary biliary cirrhosis and primary sclerosing cholangitis and those who 
require treatment with glucocorticoids for more than 3 months. Calcium and 
vitamin D supplementation and use of bisphosphonates can improve bone 
mineral density without producing serious side effects.41 
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4. Thyroid disease. 
      Liver plays an important role in metabolism of thyroid hormones and 
also in producing circulating thyroid hormone binding globulin. Thyroid 
hormones are produced from a precursor glycoprotein Thyroglobulin (TG). The 
TG gets iodinated after secretion into the thyroid follicles. The TG gets 
iodinated on the tyrosine residues and are coupled via an ether linkage. There is 
reuptake of TG into the follicular cells and proteolysis with resultant release of 
T3 and T4.18,39  
     TSH is responsible for regulation of thyroid gland function. It exerts its 
action via TSH receptor which is a G protein coupled receptor. Other factors 
regulating thyroid hormone synthesis includes insulin like growth factor – I, 
epidermal growth factor, transforming growth factor B, endothelins and various 
cytokines.18,39,40 
 
 
 
 
 
 
 
(Continued) 
 T4 is produced 20 times more than T3. 
binding globulin (TBG),
increase the circulation pool of thyroid
helps in delivery of thyroid hormones to various tissues.
 TBG carries 80%
affinity for T4. 
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They are bound to thyroxine 
 Transthyretin (TTR), and albumin. Binding proteins 
 hormone, prolongs their half life and 
 
 of circulating pool of thyroid hormones with greater 
 
 Albumin has relatively lower affinity for thyroid hormones and binds 
10% of T4 and 30% of
approximately 99.98% of T4 and 99.7% 
PROPERTIES OF THYROID HORMONES
  T4 acts as precursor for T3. T4 is converted to T3 by the deiodinase 
enzymes. Type 1 deiodinase enzyme is located in thyroid gland, liver and 
kidneys. It has low affinity for T4. Type 2 deiodinase enzyme has higher 
affinity towards T4 and is found in pitui
gland. Type 3 deiodinase enzyme is responsible for inactivation of T4  and T3 
and is the most important source for rT3. Liver plays a pivotal role in 
metabolism and circulation of thyroid hormone by producing Thyroi
globulin. It also plays an important role in producing T3 by action of the 
enzyme 5’deiodinase which 
rT3. Low free T3 syndrome is frequently found in patients with cirrhosis and it 
49 
 T3. TTR carries 10% T4 and very little T3. In toto 
 T3 are protein bound. 
 
tary gland, brain, brown fat and thyroid 
is a selenium dependent enzyme a
 
 
d binding 
nd also produces 
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is characterized by low levels of T3, increased rT3 and decreased T3:T4 ratio. 
The low levels of T3 is an adaptive response to reduce the basal metabolic rate 
of hepatocytes and preserve the liver function. Low T3 levels are also 
associated with low normal levels of fT4 and TSH levels in the normal or high 
normal range. There is an inverse correlation between the levels of T3 and the 
Child Pugh class and score.  Loss of peripheral deiodination is the principal 
cause of decrease T3 levels.2,3,10,22  
  Poor nutrition has also been linked to the low levels of fT3 in 
circulation. Release of cytokines like IL6, alcohol consumption have also been 
linked to the low levels of fT3 in blood. Free T4 and TSH levels are not found 
to be significantly related to the Child Pugh class or scoring.19,24,32 
  A significant inverse correlation also exists between the levels of free T3 
and MELD scoring. The levels of free T3 were significantly lower in 
decompensated cirrhosis in comparison to compensated cirrhosis. In conclusion 
serum free T3 levels can be used as a reliable prognostic indicator in patients 
with cirrhosis.12,13 
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MATERIALS AND METHODS 
Study Centre        :      Institute of Internal Medicine, Madras Medical  
 College and Rajiv Gandhi Government General  
 hospital. 
Study Design        :       Single centre observational prospective study. 
Venue                   :        Rajiv Gandhi Government General Hospital,  
  Chennai. 
Duration               :        Study conducted from June 2017 to November  
  2017. 
Sample size was calculated using the formula 4*pq/d,  where p denotes 
the prevalence of the disease, q = 1-p and d denotes the error range. About 60 
patients admitted to the medical wards with the diagnosis of decompensated 
chronic liver disease were chosen. A complete history was taken from the 
patients and the attenders including history of chronic kidney disease, previous 
history of treatment for hypo/hyperthyroidism, history of coronary artery 
disease. Basic blood investigations were done including  a complete blood 
count, liver function test, pt/inr, renal function test, portal venous doppler, 
ultrasound abdomen and thyroid function test with measurement of serum free 
T3, free T4 and TSH.  
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A thorough physical examination was done and the degree of ascites and 
encephalopathy were quantified. Child Pugh score was calculated. Patients 
were treated as per established protocols. 
Inclusion criteria:                
 Patients with a diagnosis of decompensated chronic liver disease 
admitted in medical wards. 
Exclusion criteria:                
              Patients with cardiac failure, patients with chronic kidney disease, 
patients with pre existing thyroid dysfunction (hypo/hyperthyroidism) and 
patients who are terminally ill. 
Statistical analysis plan:         
             Data analysed using statistical package – SPSS software 
Consent:                                 
            Written informed consent was obtained from the participating 
patients/attenders. 
Ethical committee approval: 
           Institutional Ethical Committee of Madras Medical College approved 
the study. 
 
  
 
 
OBSERVATION AND RESULTS 
 
  
 OBSERVATION AND RESULTS
Table
AGE_GROUP
30-40 YEARS
41-50 YEARS
ABOVE 50 
YEARS
TOTAL
 
 
 
 
 
 
26.7%
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 1 : Age groups in the study population
 FREQUENCY PERCENT
 15 25.0
 29 48.3
 
16 26.7
 60 100.0
25%
48.3%
AGE IN YEARS
30
41
ABOVE 50 YEARS
 
 
 
 
 
 
 
-40 YEARS
-50 YEARS
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Table 2 : Gender distribution in the study population 
 
 
GENDER FREQUENCY PERCENT 
MALE 46 76.7 
FEMALE 14 23.3 
TOTAL 60 100.0 
 
 
 
    
  
76.7%
23.3%
GENDER
MALE
FEMALE
55 
 
 
Table 3 : Ascites in the study population 
ASCITES FREQUENCY PERCENT 
ABSENT 20 33.3 
MILD 25 41.7 
TENSE 15 25.0 
TOTAL 60 100.0 
 
 
 
 
 
 
  
  
33.3%
41.7%
25%
ASCITES
ABSENT
MILD
TENSE
56 
 
 
Table 4 : Encephalopathy in the study population 
 
ENCEPHALOPATHY FREQUENCY PERCENT 
ABSENT 31 51.7 
GRADE 1 13 21.7 
GRADE 2 10 16.7 
GRADE 3 5 8.3 
NONE 1 1.7 
TOTAL 60 100.0 
 
 
 
 
 
 
 
 
 
51.7%
21.7%
16.7%
8.3%
1.7%
ENCEPHALOPATHY
ABSENT
GRADE 1
GRADE 2
GRADE 3
NONE
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Table 5 : Child Pugh class in the study population 
 
CHILD PUGH 
CLASS FREQUENCY PERCENT 
A 7 11.7 
B 20 33.3 
C 33 55.0 
TOTAL 60 100.0 
 
 
 
 
 
 
11.7%
33.3%55%
CHILD PUGH CLASS
A
B
C
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Table 6: Analysis of thyroid profile in patients with ascites in the study 
 
  
DESCRIPTIVES  
ASCITES N 
M
EA
N
 
ST
D
.
 
D
EV
IA
TI
O
N
 
ST
D
.
 
ER
R
O
R
 
95
%
 
CO
N
FI
D
EN
CE
 
IN
TE
R
V
A
L 
FO
R
 
M
EA
N
 
M
IN
IM
U
M
 
M
A
X
IM
U
M
 
 
LOWER 
BOUND 
UPPER 
BOUND 
 
F VALUE 
FREE T3 
(PG/ML) 
ABSENT 20 2.9590 .41521 .09284 2.7647 3.1533 2.05 3.46 59.440** 
MILD 25 1.7924 .49224 .09845 1.5892 1.9956 1.22 3.22 
TENSE 15 1.4340 .40597 .10482 1.2092 1.6588 1.08 2.34 
TOTAL 60 2.0917 .77208 .09968 1.8922 2.2911 1.08 3.46 
FREE 
T4(NG/DL) 
ABSENT 20 1.9930 .24938 .05576 1.8763 2.1097 1.32 2.36 60.459** 
MILD 25 1.3476 .25770 .05154 1.2412 1.4540 1.02 2.09 
TENSE 15 1.1727 .19587 .05057 1.0642 1.2811 .86 1.54 
TOTAL 60 1.5190 .41863 .05404 1.4109 1.6271 .86 2.36 
TSH(UIU/ML) ABSENT 20 2.2086 .31146 .06964 2.0628 2.3544 1.90 2.91 37.976** 
MILD 25 2.8892 .41795 .08359 2.7167 3.0618 2.00 3.89 
TENSE 15 3.3475 .44032 .11369 3.1037 3.5914 2.68 4.23 
TOTAL 60 2.7769 .58815 .07593 2.6250 2.9289 1.90 4.23 
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Free T3 levels in different clinical grades of ascites in the study 
 
 
Free T4 levels in different clinical grades of ascites in the study 
 
 
 
2.96
1.79
1.43
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
ABSENT MILD TENSE
FREE T3 (PG/ML)
1.99
1.35
1.17
0.00
0.50
1.00
1.50
2.00
2.50
ABSENT MILD TENSE
FREE T4(NG/DL)
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Serum TSH levels in different clinical grades of ascites in the study 
 
 
 
 
 
 
 
 
 
 
(Continued) 
2.21
2.89
3.35
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
ABSENT MILD TENSE
TSH(uIU/ML)
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Table 7: Analysis of thyroid profile in patients with encephalopathy 
 in the study 
DESCRIPTIVES  
 
 
N 
M
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N
 
ST
D
.
 
D
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M
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U
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U
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LOWER 
BOUND 
UPPER 
BOUND 
 
FREE T3 
(PG/ML) 
ABSENT 31 2.6639 .59487 .10684 2.4457 2.8821 1.62 3.46 
23.338** 
GRADE 
1 
13 1.6069 .36447 .10109 1.3867 1.8272 1.12 2.43 
GRADE 
2 
10 1.4010 .29920 .09462 1.1870 1.6150 1.22 2.22 
GRADE 
3 
5 1.1800 .07616 .03406 1.0854 1.2746 1.08 1.26 
NONE 1 2.1200 . . . . 2.12 2.12 
TOTAL 60 2.0917 .77208 .09968 1.8922 2.2911 1.08 3.46 
18.415** FREE 
T4(NG/DL) 
ABSENT 31 1.8165 .35132 .06310 1.6876 1.9453 1.22 2.36 
GRADE 
1 
13 1.2508 .20650 .05727 1.1260 1.3756 1.02 1.81 
GRADE 
2 
10 1.2030 .13317 .04211 1.1077 1.2983 1.02 1.47 
GRADE 
3 
5 1.0220 .10733 .04800 .8887 1.1553 .86 1.14 
NONE 1 1.4300 . . . . 1.43 1.43 
TOTAL 60 1.5190 .41863 .05404 1.4109 1.6271 .86 2.36 
19.395** 
 
TSH(UIU/ML) ABSENT 31 2.3985 .39918 .07169 2.2521 2.5450 1.90 3.13 
GRADE 
1 
13 2.9868 .40830 .11324 2.7400 3.2335 2.03 3.46 
GRADE 
2 
10 3.2128 .34886 .11032 2.9632 3.4624 2.73 3.89 
GRADE 
3 
5 3.7698 .38413 .17179 3.2928 4.2468 3.41 4.23 
NONE 1 2.4560 . . . . 2.46 2.46 
TOTAL 60 2.7769 .58815 .07593 2.6250 2.9289 1.90 4.23 
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Free T3 levels in different grades of encephalopathy in the study 
 
 
Free T4 levels in different grades of encephalopathy in the study 
 
 
2.66
1.61
1.40
1.18
2.12
0.00
0.50
1.00
1.50
2.00
2.50
3.00
ABSENT GRADE 1 GRADE 2 GRADE 3 NONE
FREE T3 (PG/ML)
1.82
1.25
1.20
1.02
1.43
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
2.00
ABSENT GRADE 1 GRADE 2 GRADE 3 NONE
FREE T4(NG/DL)
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Serum TSH levels in different grades of encephalopathy in the study 
 
 
 
 
 
 
 
 
 
 
(Continued) 
2.40
2.99
3.21
3.77
2.46
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
ABSENT GRADE 1 GRADE 2 GRADE 3 NONE
TSH(uIU/ML)
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Table8: Analysis of thyroid profile and serum bilirubin, albumin and INR 
in the study 
 
 
FREE T3 
(PG/ML) 
FREE 
T4(NG/DL) 
TSH(UIU/ML) 
TOTAL 
BILIRUBIN 
(MG/DL) 
PEARSON CORRELATION -.777 -.729 .732 
SIG. (2-TAILED) .000 .000 .000 
N 60 60 60 
 
ALBUMIN 
(G/DL) 
PEARSON CORRELATION .840 .819 -.801 
SIG. (2-TAILED) .000 .000 .000 
N 60 60 60 
 
INR 
PEARSON CORRELATION -.825 -.777 .782 
SIG. (2-TAILED) .000 .000 .000 
N 60 60 60 
 
CHILD PUGH 
SCORE 
PEARSON CORRELATION -.964 -.923 .879 
SIG. (2-TAILED) .000 .000 .000 
N 60 60 60 
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Correlation between Free T3 levels and Bilirubin levels in the study
 
 
Correlation between Free T3 and Albumin levels in the study 
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Correlation between Free T3 and INR levels in the study 
 
 
Correlation between Free T3 levels and the Child Pugh score in the study 
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Correlation between Free T4 levels and Bilirubin levels in the study 
 
 
Correlation between Free T4 levels and Albumin levels in the study 
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Correlation between Free T4 levels and INR in the study 
 
 
Correlation between Free T4 levels and Child Pugh score in the study 
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Correlation between serum TSH levels and Total Bilirubin in the study 
 
 
Correlation between serum TSH levels and Albumin levels in the study 
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Correlation between serum TSH levels and Child Pugh score 
 
 
Correlation between serum TSH levels and INR in the study 
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Table 9: Analysis of Thyroid profile and the Child Pugh  
classes  in the study 
 
DESCRIPTIVES  
CHILD PUGH 
 CLASS 
N MEAN 
ST
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.
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LOWER 
BOUND 
UPPER 
BOUND 
 
FREE T3 
(PG/ML) 
A 7 3.2557 .14164 .05353 3.1247 3.3867 3.02 3.46 
127.314** 
B 20 2.6865 .43635 .09757 2.4823 2.8907 2.05 3.35 
C 33 1.4842 .29020 .05052 1.3813 1.5871 1.08 2.12 
TOTAL 60 2.0917 .77208 .09968 1.8922 2.2911 1.08 3.46 
FREE T4 
(NG/DL) 
A 7 2.1114 .07198 .02721 2.0449 2.1780 1.98 2.18 
78.986** 
B 20 1.8280 .30871 .06903 1.6835 1.9725 1.32 2.36 
C 33 1.2061 .16769 .02919 1.1466 1.2655 .86 1.76 
TOTAL 60 1.5190 .41863 .05404 1.4109 1.6271 .86 2.36 
TSH 
(UIU/ML) 
A 7 2.0561 .11032 .04170 1.9541 2.1582 1.90 2.23 
37.594** 
B 20 2.3892 .38108 .08521 2.2109 2.5675 1.90 2.93 
C 33 3.1648 .43187 .07518 3.0117 3.3180 2.44 4.23 
TOTAL 60 2.7769 .58815 .07593 2.6250 2.9289 1.90 4.23 
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Free T3 levels and Child Pugh class in the study 
 
 
 
Free T4 levels and Child Pugh class in the study 
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Serum TSH levels and Child Pugh class in the study 
 
 
      
 
 
 
 
 
 
 
 
 
 
(Continued) 
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Table 10: Analysis of Free T3 levels and Bilirubin, Albumin,  
Child Pugh scores in the study 
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R
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FREE_T3_ 
PGML 
PEARSON 
CORRELATION -.825
**
 -.777** .840** -.964** 
P VALUE P<0.01 P<0.01 P<0.01 P<0.01 
N 60 60 60 60 
**. CORRELATION IS SIGNIFICANT AT THE 0.01 LEVEL (2-TAILED). 
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Correlation of Free T3 levels with total bilirubin in the study 
 
 
 
 
Correlation of Free T3 levels with INR in the study
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Correlation of Free T3 levels with the Child Pugh scores in the study 
 
 
 
 
 
 
 
 
 
(Continued) 
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Table12: Distribution of Child Pugh 
PEARSON CHI-SQUARE=5.766 P= 0.217
 
 
Analysis of Child Pugh class in different age groups in 
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33 60 
 100.0% 100.0% 
  
 
Table 13: Gender wise distribution of Child Pugh class in the study
PEARSON CHI-SQUARE=0.221  P= 0.895
 
Analysis of Child Pugh class among the male and female genders in the 
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 TOTAL 
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33 60 
100.0% 100.0% 
  
Table 14:Distribution of 
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PEARSON CHI-SQUARE=39.726** P<0.001
 
Analysis of different grades of Ascites and the Child Pugh class 
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Table 15: Distribution of Encephalopathy in various Child Pugh class in 
the study 
 
CROSSTAB 
 CHILD_PUGH_CLASS TOTAL 
A B C 
ENCEPHALOPATHY 
ABSENT 
COUNT 7 17 7 31 
% WITHIN 
CHILD_PUGH_CLASS 
100.0% 85.0% 21.2% 51.7% 
GRADE 
1 
COUNT 0 2 11 13 
% WITHIN 
CHILD_PUGH_CLASS 
0.0% 10.0% 33.3% 21.7% 
GRADE 
2 
COUNT 0 1 9 10 
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0.0% 5.0% 27.3% 16.7% 
GRADE 
3 
COUNT 0 0 5 5 
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COUNT 7 20 33 60 
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PEARSON CHI-SQUARE=28.173** P<0.001 
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class in the study 
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(Continued) 
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Table 11: Distribution of Free T3 levels and Bilirubin, Albumin  
and INR in the study 
 
 
 
  
DESCRIPTIVES 
 
 N MEAN 
STD. 
DEVIATION 
STD. 
ERROR 
95% 
CONFIDENCE 
INTERVAL FOR 
MEAN 
MIN. MAX. 
 
LOWER 
BOUND 
UPPER 
BOUND 
F 
VALUE
P 
VALUE
TOTAL_ 
BILIRUBIN_MGDL 
A 7 4.2000 3.83580 1.44979 .6525 7.7475 .90 11.20 
1.123 0.333 B 20 3.7050 2.97170 .66449 2.3142 5.0958 1.10 13.10 
C 32 5.0688 3.27753 .57939 3.8871 6.2504 .80 13.20 
TOTAL 59 4.5034 3.25020 .42314 3.6564 5.3504 .80 13.20 
ALBUMIN_GDL 
A 7 2.6000 .51962 .19640 2.1194 3.0806 1.80 3.30 
0.393 0.677 B 20 2.6425 .44876 .10035 2.4325 2.8525 2.00 3.50 
C 32 2.5369 .38343 .06778 2.3986 2.6751 1.80 3.40 
TOTAL 59 2.5802 .41822 .05445 2.4712 2.6892 1.80 3.50 
INR 
A 7 1.5786 .31898 .12056 1.2836 1.8736 1.14 2.05 
0.975 0.384 B 20 1.4290 .27209 .06084 1.3017 1.5563 .92 1.95 
C 32 1.5278 .30223 .05343 1.4188 1.6368 .92 1.96 
TOTAL 59 1.5003 .29412 .03829 1.4237 1.5770 .92 2.05 
FREE_T3_PGML 
A 7 2.0129 .87408 .33037 1.2045 2.8213 1.08 3.22 
0.345 0.710 B 20 2.2020 .73547 .16446 1.8578 2.5462 1.22 3.35 
C 32 2.0250 .79618 .14075 1.7379 2.3121 1.12 3.46 
TOTAL 59 2.0836 .77613 .10104 1.8813 2.2858 1.08 3.46 
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DISCUSSION 
The observational study done at MMC and RGGGH, Chennai during 
June 2017 to November 2017 in the Institute Of Internal Medicine studied 
thyroid dysfunction in patients with decompensated chronic liver disease. The 
correlation between the levels of free T3 in the serum and the Child Pugh score 
was analysed. A total of 60 inpatients admitted to the medical wards in 
RGGGH were enrolled in the study. 
After getting informed consent from the patients or their relatives 
routine investigations were done which included complete blood hemogram, 
renal function tests, pt/apt and inr, liver function testing, portal venous 
Doppler, usg abdomen,  thyroid profile with free T3, free T4 and TSH. After 
ensuring that patient did not have any confounding factors, the data was 
analysed for establishing the statistical significance of levels of serum T3 as a 
prognostic indicator in patients with decompensated liver disease. 
Out of the 60 patients included in the study , 46  patients were male and 
14 patients were female. 25% were in the 30 to 40 years age group, 48.3% were 
in the 41 to 50 years age group and 26.7% were in the above 50 years age 
group. The median age group was 45.2 years. Out of 60 patients,  33.3% had  
no ascites,  41.7% had  mild  ascites  and 25% had tense ascites.  
In the study population 51.7% patients had no encephalopathy, 21.7% 
patients had grade 1 hepatic encephalopathy, 16.7% had grade  
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2 encephalopathy, 8.3% patients had grade 3 encephalopathy. The grading was 
done according to the West Haven criteria. 
The proportion of patients in Child Pugh class A were 11.7%, class B 
were 33.3% and class C were 55%. 
It was observed that as the degree of ascites increases, the values of 
serum free T3 tend to decrease and become lesser than the normal. The levels 
of serum free T4 also shows a decreasing trend with the increase in degree of 
ascites. However the levels of free T4 tends to remain in the low normal range. 
Serum TSH tends to increases as the degree of ascites worsens but tends to 
remain in the high normal range.19 
As far as the encephalopathy is concerned, the serum T3 levels shows a 
declining trend and tends to remain below the normal range as the degree of 
encephalopathy worsens. The levels of free T4 and TSH tend to remain within 
the normal range with levels of free T4 approaching a low normal level and 
levels of TSH reaching a high normal level with worsening degrees of hepatic 
encephalopathy.17 
In case of hyperbilirubinemia the levels of  free T3 decreases with 
increase in the serum bilirubin and falls below the normal, whereas the levels 
of free T4 and TSH tends to remain normal. 
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As the hypoalbuminemia worsens the level of serum free T3 falls below 
the normal, whereas the level of free T4 and TSH tends to remain fairly 
normal. As the coagulopathy in the study population worsens (measured by the 
INR) the levels of free T3 falls well below the normal level, with normal levels 
of T4 and TSH. 
Person correlation was calculated to determine the degree of correlation 
between the levels of free t3 and variables in Child Pugh score and to analyse 
the statistical significance. 
The pearson correlation between Free T3 and serum bilirubin was found 
to be - 0.777 with a p value of <0.01. The pearson correlation for INR and free 
T3  was found to be -0.825 with a p value <0.01. Similarly the pearson 
correlation was found to be -0.840 for serum albumin and free T3 with a p 
value of <0.01. 
Finally the pearson correlation was applied for the total Child Pugh 
scores and serum free T3 levels which was -0.964 with a p value of <0.01. The 
statistical analysis of the data shows that a significant association exists 
between the Child Pugh score and free T3 levels in the serum of patients with 
decompensated chronic liver disease. 12,13,23,32 
This goes in line with the findings of the study published in june 2013 
from Asian Institute of Gastroenterology, which was a retrospective study with 
one group of 310 cirrhotics (211 males and 99 females) between age 20 to 80 
years and another group of healthy subjects aged 20 to 80 years (145 males and 
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105 females). The thyroid hormone levels were determined and possible 
relation between hypothyroidism and liver cirrhosis was looked for. After the 
analysis of their study results, it was found that cirrhotics had low levels of T3 
with normal levels of T4 and TSH. The levels of freeT3 concentration seemed 
to have a good correlation with the state of the chronic liver disease and it also 
estimated the progress of liver disease. 
Another study by Doctor Sudhir Kumar et al which enrolled 102 
patients with cirrhosis (73 males and 29 females) analysed the thyroid 
abnormalities in chronic liver disease. The study concluded that lower T3 
levels were associated with more severe liver injury and thyroid function 
testing should be carried out in all patients with cirrhosis to assess the severity 
and determine the prognosis.42 
A Study by Doctor Sandeep Kharb et al published in Indian Journal of 
Endocrinology and Metabolism analysed the thyroid and gonadal dysfunction 
in patients with liver disease revealed significantly low T3 levels compared to 
the controls.3 
The value of serum T3 falls below the normal range and decreases 
proportionately as the Child Pugh score increases, thus validating the role of 
measuring serum free T3 levels in patients with chronic liver disease and using 
it to assess prognosis with various levels of decompensation (as evidenced by 
worsening Child Pugh scores). 
 
  
 
 
CONCLUSION 
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CONCLUSION 
1. The mean age of patients admitted with decompensated chronic liver 
disease in the study population 45.2 years. 
2. More than half of the patients belonged to Child Pugh class C. 
3. Serum free T3 levels were found to have significant correlation with 
levels of albumin, bilirubin, INR in the study population. 
4. Serum free T3 levels had a significant correlation with the Child Pugh 
score thus validating the use of measuring serum free T3 levels to assess 
the disease prognosis in patients with decompensated chronic liver 
disease. 
 
 
 
 
 
 
 
 
 
  
 
 
LIMITATIONS 
 
 
 
 
 
88 
 
 
LIMITATIONS 
1.  It is a single centred study. We need multicentric study involving 
patients of different geographical areas to have a better analysis. 
2. Liver biopsy/elastography was not done to confirm the diagnosis of 
cirrhosis. 
3. Detailed thyroid profile with measurement of reverse T3, thyroglobulin 
were not carried out. 
4. It is a cross sectional study, hence it cannot assess whether improvement 
of liver function with treatment is associated with an improvement in 
thyroid profile and serum free T3 levels. 
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A STUDY ON THYROID FUNCTION TESTS IN DECOMPENSATED 
LIVER DISEASE AND IMPLICATON OF FREE T3 AS A 
PROGNOSTIC INDICATOR 
PROFORMA 
NAME  : 
AGE   : 
SEX   : 
IP NO   : 
SYMPTOMS  
FEVER 
YELLOWISH DISCOLORATION OF EYES 
ITCHING 
H/S/O HYPO OR HYPER THYROIDISM (IF ANY) 
ABDOMINAL DISTENTION  
VOMITING BLOOD/PASSING BLACK TARRY STOOLS 
ALTERED SENSORIUM 
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PAST HISTORY 
K/C OF CAD/ CKD/ THYROID DYSFUNCTION 
PERSONAL HISTORY 
SMOKING OR ALCOHOL INTAKE. 
GENERAL EXAMINATION 
ASSESMENT OF LEVEL OF CONSCIOUNESS 
ORIENTATION 
MARKERS OF LIVER CELL FAILURE (IF ANY) 
SYSTEMIC EXAMINATION 
EXAMINATION OF UPPER GI TRACT 
INSPECTION OF ABDOMEN 
PALPATION OF ABDOMEN 
PERCUSSION OF ABDOMEN 
AUSCULTATION OF ABDOMEN 
CVS   : 
RS   : 
CNS   : 
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INVESTIGATIONS 
CBC     : 
RFT     : 
LFT     : 
URINE R/E    : 
PT/APTT/INR   : 
VIRAL MARKERS   : 
THYROID FUNCTION TESTS : 
CHILD PUGH SCORE 
USG ABDOMEN 
PORTAL VENOUS DOPPLER 
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INFORMATION SHEET 
We are conducting a study on “THYROID FUNCTION TESTS IN 
DECOMPENSATED LIVER DISEASE AND IMPLICATION OF 
SERUM FT3 AS A PROGNOSTIC INDICATOR..” among patients 
attending Rajiv Gandhi Government General Hospital, Chennai and for that 
your co-operation to undergo relevant investigations as per need may be 
valuable to us. The purpose of this study is to ascertain the importance of 
thyroid function tests in assesing the prognosis in decompensated liver disease 
patients. We are selecting certain cases and if you are found eligible, we would 
like to perform extra tests and you will be subjected to thyroid function tests 
which in any way do not affect your final report or management. The privacy 
of the patients in the research will be maintained throughout the study. In the 
event of any publication or presentation resulting from the research, no 
personally identifiable information will be shared. Taking part in this study is 
voluntary. You are free to decide whether to participate in this study or to 
withdraw at any time; your decision will not result in any loss of benefits to 
which you are otherwise entitled. The results of the special study may be 
intimated to you at the end of the study period or during the study if anything is 
found abnormal which may aid in the management or treatment. 
 
Signature of the Investigator          Signature/thumb impression of the  
participant 
Date  : 
Place : 
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PATIENT CONSENT FORM 
Patient may check (√) these circles 
a) I confirm that I have understood the purpose of procedure 
for the above study. I have the opportunity to ask question 
and all my questions and doubts have been answered to 
my complete satisfaction. o ❏ 
b) I understand that my participation in the study is voluntary 
and that I am free to withdraw at any time without giving 
reason, without my legal rights being affected. o ❏ 
c) I understand that sponsor of the clinical study, others 
working on the sponsor’s behalf, the ethical committee 
and the regulatory authorities will not need my permission 
to look at my health records, both in respect of current 
study and any further research that may be conducted in 
relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will 
not be revealed in any information released to third parties 
or published, unless as required under the law. I agree not 
to restrict the use of any data or results that arise from this 
study. o ❏ 
Study Detail : THYROID FUNCTION TESTS IN 
DECOMPENSATED LIVER DISEASE AND  
IMPLICATION OF SERUM FREE T3 AS A 
PROGNOSTIC INDICATOR. 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
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d) I agree to take part in the above study and to comply with 
the instructions given during the study and faithfully 
cooperate with the study team and to immediately inform 
the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual 
symptoms. o ❏ 
e) I hereby consent to participate in this study. o ❏ 
f) I hereby give permission to undergo detailed clinical 
examination and relevant investigations as required. o ❏ 
 
 
 
 
Signature/thumb impression:                                     Signature of the investigator: 
 
Patient’s Name and Address:                        Investigator’s  Name: DR.S.SABARISH. 
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1 37 MALE 4.2 3.4 1.14 ABSENT ABSENT 8 B 2.57 1.76 2.712 
2 50 FEMALE 1.6 2.2 1.25 MILD GRADE 2 9 B 2.22 1.47 2.926 
3 37 FEMALE 2.3 2.5 1.49 TENSE ABSENT 10 C 1.82 1.26 3.126 
4 70 FEMALE 0.8 2.9 0.92 MILD ABSENT 7 B 2.82 1.94 2.313 
5 41 MALE 3.9 2.6 1.66 MILD GRADE 1 11 C 1.48 1.02 3.254 
6 30 MALE 2.4 3 1.14 ABSENT ABSENT 7 B 3.34 2.16 2.092 
7 58 MALE 1.2 2 1.34 TENSE ABSENT 9 B 2.34 1.54 2.878 
8 46 FEMALE 2.5 2.9 1.44 TENSE ABSENT 9 B 2.29 1.52 2.887 
9 42 FEMALE 13.1 2.2 1.95 MILD GRADE 2 12 C 1.23 1.09 3.234 
10 51 MALE 13.2 2.1 1.86 TENSE GRADE 2 13 C 1.25 1.12 3.189 
11 42 MALE 9.2 2.3 1.93 MILD GRADE 1 12 C 1.35 1.18 3.076 
12 45 MALE 3.9 2.3 1.59 MILD ABSENT 10 C 1.99 1.35 2.897 
13 35 MALE 11.9 2.4 1.92 TENSE GRADE 1 13 C 1.12 1.02 3.331 
14 45 MALE 5.6 2.3 1.32 ABSENT ABSENT 9 B 2.05 1.32 2.912 
15 80 MALE 3.5 2.3 1.76 MILD ABSENT 11 C 1.68 1.22 2.998 
16 48 MALE 2.5 2.6 1.38 ABSENT ABSENT 8 B 2.46 1.68 2.789 
17 52 MALE 8.6 2.3 1.92 TENSE GRADE 3 14 C 1.22 1.08 3.412 
18 45 MALE 2.3 2.8 1.35 ABSENT ABSENT 7 B 3.35 2.26 1.987 
19 37 MALE 3.5 2.8 1.4 ABSENT GRADE 1 9 B 2.43 1.81 2.032 
20 40 MALE 4.5 2.2 1.32 MILD ABSENT 10 C 1.86 1.28 2.886 
21 52 MALE 1.5 3.2 1.15 ABSENT ABSENT 6 A 3.22 2.12 2.123 
22 45 MALE 7.8 2.4 1.86 TENSE GRADE 2 13 C 1.34 1.11 3.023 
23 48 FEMALE 4.2 2.5 1.77 MILD GRADE 2 12 C 1.45 1.23 2.992 
24 54 FEMALE 5.6 2.2 1.92 TENSE GRADE 1 13 C 1.26 1.07 3.456 
25 51 MALE 6.2 2.3 1.65 MILD GRADE 1 11 C 1.38 1.21 3.023 
26 48 MALE 3.3 2.6 1.54 MILD ABSENT 10 C 1.84 1.32 2.876 
27 39 FEMALE 7.6 2.2 1.78 TENSE GRADE 3 14 C 1.26 1.05 3.654 
28 47 MALE 3.5 2.5 1.54 MILD NONE 10 C 2.12 1.43 2.456 
29 48 MALE 2.2 2.8 1.25 ABSENT ABSENT 7 B 3.15 2.21 2.034 
30 47 MALE 1.6 3.2 1.15 ABSENT ABSENT 7 B 3.35 2.36 1.895 
31 42 MALE 4.6 2.2 1.52 MILD GRADE 2 11 C 1.42 1.32 2.731 
32 32 MALE 9.2 2.1 1.92 TENSE GRADE 3 14 C 1.22 1.14 3.432 
33 56 MALE 6.2 2.5 1.44 MILD GRADE 1 11 C 1.75 1.24 2.765 
34 30 MALE 2.4 2.6 1.38 ABSENT ABSENT 8 B 2.52 1.78 2.678 
35 64 FEMALE 3.2 2.8 1.25 ABSENT ABSENT 8 B 2.65 1.82 1.987 
36 32 MALE 2.5 2.6 1.36 MILD ABSENT 9 B 2.33 1.56 2.228 
37 45 MALE 1.4 3.5 1.15 ABSENT ABSENT 6 A 3.26 2.16 2.125 
38 42 MALE 3.5 2.2 1.62 TENSE GRADE 2 12 C 1.35 1.28 3.125 
39 51 MALE 3.8 2.5 1.42 MILD GRADE 1 11 C 1.52 1.42 2.442 
40 42 FEMALE 2.6 3.1 1.44 ABSENT ABSENT 7 B 2.92 2.08 2.098 
41 58 MALE 1.3 3.2 1.34 ABSENT ABSENT 6 A 3.34 2.18 1.967 
42 31 MALE 2.4 3.1 1.14 MILD GRADE 1 9 B 2.12 1.36 2.778 
43 64 FEMALE 1.1 3.2 0.92 ABSENT ABSENT 6 A 3.02 1.98 2.023 
44 43 MALE 0.9 3.3 1.66 MILD ABSENT 7 B 3.22 2.09 1.995 
45 37 MALE 4.3 2.8 1.44 MILD GRADE 1 10 C 1.76 1.22 3.098 
46 45 MALE 10.2 1.8 1.96 TENSE GRADE 3 14 C 1.12 0.98 4.123 
47 56 MALE 8.2 2.2 1.88 TENSE GRADE 2 13 C 1.22 1.14 3.674 
48 54 MALE 5.5 2.3 1.68 MILD GRADE 1 12 C 1.36 1.21 3.334 
49 44 FEMALE 4.2 2.6 1.34 TENSE ABSENT 11 C 1.62 1.42 2.675 
50 38 MALE 6.1 2.1 1.68 MILD GRADE 1 11 C 1.54 1.32 2.883 
51 42 MALE 3.4 3.1 1.22 ABSENT ABSENT 8 B 2.48 1.78 2.342 
52 50 MALE 2.1 3.2 1.14 ABSENT ABSENT 7 B 3.12 2.06 2.221 
53 44 MALE 7.3 2.1 1.78 MILD GRADE 2 12 C 1.22 1.02 3.889 
54 52 MALE 1.3 3.1 1.14 ABSENT ABSENT 6 A 3.46 2.18 2.226 
  
55 47 MALE 11.2 1.8 2.05 TENSE GRADE 3 14 C 1.08 0.86 4.228 
56 39 MALE 9.2 2.1 1.86 MILD GRADE 2 12 C 1.31 1.25 3.345 
57 45 MALE 0.9 3.4 0.96 ABSENT ABSENT 6 A 3.33 2.08 1.897 
58 48 FEMALE 1.5 2.8 1.28 ABSENT ABSENT 6 A 3.16 2.08 2.032 
59 46 FEMALE 2.1 2.6 1.44 MILD GRADE 1 10 C 1.82 1.18 3.356 
60 31 MALE 3.1 2.6 1.56 MILD ABSENT 10 C 2.02 1.76 2.456 
